Allopurinol as a possible new therapy for acute coronary syndrome
- Conditions
- Acute coronary syndromeTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2011-004996-35-GB
- Lead Sponsor
- niversity of Dundee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Age 18-85 male or female. angiographically documented coronary artery disease, a positive exercise tolerance test (ETT) a history of symptoms of chronic, stable, effort-induced angina for = 2 months. All concomitant antianginal medication will be allowed and continued unchanged during the study.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 26
Exclusion criteria will include •the inability to do an ETT due to back or leg problems, •myocardial infarction or acute coronary syndrome = 2 months, •coronary revascularization (percutaneous or CABG) = 6 months, •Left Ventricular Ejection Fraction <45%, •estimated GFR <60 ml/min or creatinine >180 mmol/ml, •significant valvular pathology, •already had gout or on allopurinol, •atrial arrhythmias or ECG abnormalities interfering with ST-segment interpretation, •previous ventricular arrhythmias on ETT, •severe hepatic disease •or on azathioprine, 6 mercaptopurine or warfarin. •Patients who have participated in any other clinical trial within the previous 30 days will be excluded. •Patients who are unable to give informed consent will also be excluded from this trial.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method